Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Subscribe To Our Newsletter & Stay Updated
